ImmunityBio (NASDAQ:IBRX) Stock Purchase Disclosed by Rep. Lisa C. McClain

Representative Lisa C. McClain (Republican-Michigan) recently bought shares of ImmunityBio, Inc. (NASDAQ:IBRX). In a filing disclosed on October 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in ImmunityBio stock on September 30th. The trade occurred in the Representative’s “CHARLES SCHWAB 401K (HANTZ) > SCHWAB 824” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 9/30/2026.
• Sold $15,001 – $50,000 in shares of Seagate Technology (NASDAQ:STX) on 9/30/2026.
• Purchased $1,001 – $15,000 in shares of Caterpillar (NYSE:CAT) on 9/28/2026.
• Purchased $1,001 – $15,000 in shares of ImmunityBio (NASDAQ:IBRX) on 9/28/2026.
• Purchased $15,001 – $50,000 in shares of Olin (NYSE:OLN) on 9/14/2026.
• Purchased $1,001 – $15,000 in shares of Novagold Resources (NYSEAMERICAN:NG) on 9/14/2026.
• Purchased $15,001 – $50,000 in shares of Transocean (NYSE:RIG) on 9/14/2026.
• Purchased $15,001 – $50,000 in shares of CACI International (NYSE:CACI) on 9/14/2026.

ImmunityBio Stock Performance

Shares of NASDAQ:IBRX opened at $9.80 on Wednesday. ImmunityBio, Inc. has a one year low of $1.95 and a one year high of $12.43. The stock has a fifty day moving average of $8.43 and a 200-day moving average of $7.92. The company has a market capitalization of $10.39 billion, a PE ratio of -10.10 and a beta of 0.02.

ImmunityBio (NASDAQ:IBRX) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). The company had revenue of $51.24 million for the quarter, compared to analysts’ expectations of $49.70 million. As a group, research analysts forecast that ImmunityBio, Inc. will post -0.44 EPS for the current fiscal year.

Insider Transactions at ImmunityBio

In related news, Director Cheryl Cohen sold 81,056 shares of the company’s stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $10.50, for a total value of $851,088.00. Following the sale, the director owned 100,309 shares in the company, valued at $1,053,244.50. This represents a 44.69% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry Simon sold 25,000 shares of the company’s stock in a transaction on Monday, October 5th. The stock was sold at an average price of $10.75, for a total value of $268,750.00. Following the sale, the director owned 2,777,788 shares of the company’s stock, valued at $29,861,221. This trade represents a 0.89% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 66.10% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of ImmunityBio in a report on Tuesday, October 6th. Jefferies Financial Group upgraded shares of ImmunityBio to a “strong-buy” rating in a research report on Friday, September 25th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $14.20.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Markowski Investments bought a new position in shares of ImmunityBio in the second quarter valued at about $29,000. GAMMA Investing LLC grew its stake in shares of ImmunityBio by 262.2% in the third quarter. GAMMA Investing LLC now owns 3,807 shares of the company’s stock worth $36,000 after purchasing an additional 2,756 shares during the last quarter. Hollencrest Capital Management bought a new stake in shares of ImmunityBio in the 2nd quarter valued at $44,000. Western Wealth Management LLC acquired a new stake in ImmunityBio during the 1st quarter worth about $44,000. Finally, Geneos Wealth Management Inc. grew its position in shares of ImmunityBio by 579.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 5,754 shares of the company’s stock worth $44,000 after buying an additional 4,907 shares during the period. 8.58% of the stock is currently owned by institutional investors.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

About ImmunityBio

ImmunityBio, Inc is a biotechnology company focused on developing and commercializing immunotherapies designed to activate and strengthen the body’s immune system against cancer and infectious diseases. The company combines cytokine-based therapies, vaccines, cellular therapies and other immune-modulating technologies in an effort to create durable treatment responses.

Its lead product, ANKTIVA (nogapendekin alfa inbakicept-pmln), is an interleukin-15 receptor agonist immune stimulator.